PRXL2B

Across TCGA pan-cancer cohorts, PRXL2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRXL2B data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRXL2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRXL2B expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where PRXL2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.694	0.962	.004	28	view →
CCRCC	DFS	Median	III,IV	0.768	0.412	.003	9	view →
UCEC	OS	Tertile	II,III,IV	0.597	1.000	.035	8	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
LSCC	OS	Quartile	II,III,IV	0.570	0.927	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRXL2B–LUAD (DFS)

Open the LUAD breakdown →